A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma.
Patrick Y WenDavid A ReardonTerri S ArmstrongSurasak PhuphanichRobert D AikenJoseph C LandolfiWilliam T CurryJay-Jiguang ZhuMichael GlantzDavid M PeereboomJames M MarkertRenato LaRoccaDonald M O'RourkeKaren FinkLyndon KimMichael GruberGlenn J LesserEdward PanSantosh KesariAlona MuzikanskyClemencia PinillaRadleigh G SantosJohn S YuPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
PFS was significantly improved in ICT-107-treated patients with maintenance of QoL. Patients in the HLA-A2 subgroup showed increased ICT-107 activity clinically and immunologically.
Keyphrases
- newly diagnosed
- placebo controlled
- double blind
- dendritic cells
- end stage renal disease
- phase iii
- clinical trial
- chronic kidney disease
- ejection fraction
- study protocol
- squamous cell carcinoma
- randomized controlled trial
- prognostic factors
- peritoneal dialysis
- immune response
- regulatory t cells
- radiation therapy
- phase ii study
- locally advanced